Remote psychophysical testing of smell in patients with persistent olfactory dysfunction after COVID-19

Martončíková, Marcela; Doležal, Pavel; Fabianová, Kamila; Karhánek, Miloslav; Gálik, Ján; Raček, Adam; Popovičová, Alexandra; Račeková, Enikő

doi:10.1038/s41598-023-41395-9

Cited by 2 publications

(1 citation statement)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study also found a higher prevalence of hyposmia than anosmia (41.9% and 30.2% respectively). The higher prevalence of hyposmia when compared to anosmia (23.2% versus 18.3%) was also found in the study by [23].…”

Section: Discussionsupporting

confidence: 70%

Long Covid-19 Syndrome: the Prevalence of Neuropsychiatric Symptoms in Patients with Olfactory Disorders

Santos Sales,

Beiral Hammerle,

da Silva Souza

et al. 2023

View full text Add to dashboard Cite

Background: Among the frequently reported symptoms in long-term COVID-19 syndrome, we can highlight olfactory disorders depression, anxiety, and fatigue. OD can affect people's physical and mental health and can lead to neuropsychiatric symptoms. Objective: Determine the prevalence of symptoms of depression, anxiety, and fatigue in patients with olfactory disorders induced by long-term COVID-19; and investigate this impact on the quality of life. Methods: The study included 30 patients with confirmed long-term COVID-19, with persistent complaints of olfactory dysfunction. OD was evaluated by the connecticut smell test. Neuropsychiatric disorders were evaluated by the fatigue severity and hospital anxiety and depression scales. Quality of life was accessed using the SF-36. Results: 70% of the patients had different degrees of hyposmia and 20% had anosmia. The most prevalent symptom was depression with 66.7% of the sample. More than half of patients also had symptoms of anxiety and fatigue (53,3% both). The most affected dimensions of SF-36 were emotional, vitality, role physical and mental health (36.6 ± 44.0, 44.3 ± 28.7, 47.5 ± 42.7, 49.8 ± 24.7 respectively). There was a moderate negative correlation between symptoms of depression and the physical role and mental health dimension. There was a moderate negative correlation between anxiety and general health, vitality, social functioning, and mental health dimensions. Symptoms of fatigue obtained a moderate negative correlation in the physical function dimension. Conclusion: The prevalence of symptoms of depression, anxiety and fatigue is high in patients with olfactory disorders induced by long-term COVID-19, with a negative impact on the quality of life of these patients, highlighting the role emotional aspect.

show abstract

Section: Discussionsupporting

confidence: 70%

Long Covid-19 Syndrome: the Prevalence of Neuropsychiatric Symptoms in Patients with Olfactory Disorders

Santos Sales,

Beiral Hammerle,

da Silva Souza

et al. 2023

View full text Add to dashboard Cite

show abstract

Neurological Complications of COVID-19 Infection: A Comprehensive Review

Brauer,

Paika,

Kotwani

et al. 2024

Cureus

View full text Add to dashboard Cite

The COVID-19 pandemic is well on its way to reaching endemic status across the globe. While the medical community’s understanding of the respiratory complications induced by COVID-19 is improving, there is still much to be learned about the neurological manifestations associated with COVID-19 infection. This review aimed to compile relevant, available evidence of COVID-19-induced neurological complications and to provide information for each complication regarding symptomology, progression patterns, demographic risk factors, treatment, and causative mechanism of action when available. Data for this review was collected using a confined search on PubMed using the keywords [“COVID-19” OR “SARS-CoV-2”] AND [“neurological complications” OR “olfactory symptoms” OR “gustatory symptoms” OR “myalgia” OR “headache” OR “dizziness” OR “stroke” OR “seizures” OR “meningoencephalitis” OR “cerebellar ataxia” OR “acute myelitis” OR “Guillain Barré Syndrome” OR “Miller Fisher Syndrome” OR “Posterior Reversible Encephalopathy Syndrome”] between 2019 and 2023. A wide range of neurological manifestations impact a significant percentage of COVID-19 patients, and a deeper understanding of these manifestations is necessary to ensure adequate management. The most common neurological complications identified consist of olfactory and gustatory dysfunctions, myalgia, headache, and dizziness, while the most severe complications include stroke, seizures, meningoencephalitis, Guillain-Barré syndrome, Miller Fisher syndrome, acute myelitis, and posterior reversible encephalopathy syndrome. While this review effectively provides a roadmap of the neurological risks posed to COVID-19 patients, further research is needed to clarify the precise incidence of these complications and to elucidate the mechanisms responsible for their manifestation.

show abstract

Remote psychophysical testing of smell in patients with persistent olfactory dysfunction after COVID-19

Cited by 2 publications

References 63 publications

Long Covid-19 Syndrome: the Prevalence of Neuropsychiatric Symptoms in Patients with Olfactory Disorders

Long Covid-19 Syndrome: the Prevalence of Neuropsychiatric Symptoms in Patients with Olfactory Disorders

Neurological Complications of COVID-19 Infection: A Comprehensive Review

Contact Info

Product

Resources

About